| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| bretyliumtosylat 50 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
|
| bretyliumtosylat 50 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
|
| bretyliumtosylat 50 mg/ml injektionsvæske, opløsning, 10 ml hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
|
| bretyliumtosylat 50 mg/ml injektionsvæske, opløsning, 200 ml flaske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
|
| bretyliumtosylat 50 mg/ml injektionsvæske, opløsning, 50 ml hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
|
| bretyliumtosylat 50 mg/ml injektionsvæske, opløsning, 400 ml flaske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
|
| Product containing precisely bretylium tosylate 500 milligram/10 milliliter conventional release solution for injection syringe |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely bretylium tosylate 500 milligram/10 milliliter conventional release solution for injection syringe |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
1 |
| Bretylium tosilate 50 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
1 |
| Bretylium tosilate 50 mg/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Bretylium tosylate (substance) |
Inferred relationship |
Some |
1 |
FHIR